Gao‐Jun Teng

机构：Zhongda Hospital Southeast University, Zhongshan Hospital, Southeast University · ORCID：0000-0001-5800-3640

发表论文 82 篇 · 总被引 2781 次 · h-index 23

代表论文

• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 516)
• Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001) (2023 · Signal Transduction and Targeted Therapy · 被引 295)
• Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025 · The Lancet · 被引 269)
• Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study (2024 · EClinicalMedicine · 被引 156)
• Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study (2023 · European Radiology · 被引 90)
• Combination locoregional and systemic therapies in hepatocellular carcinoma (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 86)